A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Conditions

Multiple Myeloma · Myeloma · Myeloma Multiple

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco, California, United States

    Contact: Study coordinator (Phu Lam) · phu.lam@ucsf.edu · 415-858-7994
    Contact: Principal Investigator (Alfred Chung, MD)
  • Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States

    Contact: Study coordinator (Ahsan Rasheed) · rasheed.ahsan@mayo.edu · 904-953-2000
    Contact: Principal Investigator (Vivek Roy, MD)
  • The Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

    Contact: Study coordinator (Geraldine Onwuzor) · chika.geraldine.onwuzor@emory.edu · 404-778-5144
    Contact: Principal Investigator (Sagar Lonial, MD, FACP)
  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Andrew Yee, MD) · 617-724-4000
    Contact: Principal Investigator (Andrew Yee, MD)
  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Yuxin Liu, MD) · yuxin_liu@dfci.harvard.edu
    Contact: Principal Investigator (Yuxin Liu, MD)
  • Mayo Clinic - Transplant Center - Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Thomas Nelson) · nelson.thomas2@mayo.edu · 855-776-0015
    Contact: Principal Investigator (David Dingli, MD, PhD)
  • Hackensack University Medical Center, Hackensack, New Jersey, United States

    Contact: Study coordinator (Palka Anand) · Palka.Anand@hmhn.org · 551-996-3040
    Contact: Principal Investigator (David S Siegel, MD, PhD)
  • Memorial Sloan-Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Mary Silverberg) · silverb1@mskcc.org
    Contact: Study coordinator (Sharon Kim) · kims13@mskcc.org
    Contact: Principal Investigator (Saad Usmani, MD, FACP)
  • Atrium Health, Levine Cancer Institute, Charlotte, North Carolina, United States

    Contact: Study coordinator (Missy Leahy) · melissa.leahy@advocatehealth.org
    Contact: Principal Investigator (Cindy Varga, MD)
  • Duke University Hospital, Durham, North Carolina, United States

    Contact: Study coordinator (Jen Tichon) · jennifer.tichon@duke.edu · 919-660-7262
    Contact: Principal Investigator (Cristina Gasparetto, MD)
  • University of Pennsylvania, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Sara Whittington) · sara.whittington@pennmedicine.upenn.edu
    Contact: Principal Investigator (Ed Stadtmauer, MD)
  • Tennessee Oncology, Nashville, Tennessee, United States

    Contact: Study coordinator (Austin Windsor) · awindsor@tnonc.com · 629-278-3554
    Contact: Principal Investigator (Jesus Berdeja, MD)
  • University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States

    Contact: Study coordinator (Aimaz Afrough, MD) · aimaz.afrough@utsouthwestern.edu · 833-722-6237
    Contact: Principal Investigator (Aimaz Afrough, MD)
  • University Health Network (UHN) - Princess Margaret Cancer Centre (Princess Margaret Hospital), Toronto, Ontario, Canada

    Contact: Study coordinator (Saima Dean) · saima.dean@uhnresearch.ca
    Contact: Principal Investigator (Suzanne Trudel, MSc, MD)
  • Universitaire de Lille, Villeneuve-d'Ascq, France, France

    Contact: Study coordinator (Salomon Manier, MD) · Salomon.manier@chru-lille.fr · 03 59 50 75 69
    Contact: Principal Investigator (Salomon Manier, MD)
  • Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu, Nantes, France

    Contact: Study coordinator (Cyrille Touzeau, MD) · cyrille.touzeau@chu-nantes.fr · 33 (0) 2 40 08 32 71
    Contact: Principal Investigator (Cyrille Touzeau, MD)
  • Centre Hospitalier Universitaire de Poitiers (CHU de Poitiers), Poitiers, France

    Contact: Study coordinator (Romane Giraud) · Romane.giraud@chu-poitiers.fr · +33 5 16 60 43 06
    Contact: Principal Investigator (Xavier Leleu, MD)
  • Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France

    Contact: Principal Investigator (Pierre Bories, MD)
  • Clínica Universidad de Navarra, Pamplona, Navarre, Spain

    Contact: Study coordinator (Ana Valcarcel) · avalcarcelg@unav.es
    Contact: Principal Investigator (Paula Rodriguez, MD, PhD)
  • Hospital ClÃ-nic de Barcelona, Barcelona, Spain

    Contact: Study coordinator (Julio Vidal) · contratoshemato@recerca.clinic.cat · +34 93 227 5484
    Contact: Principal Investigator (Laura Rosinol, MD, PhD)
  • Hospital Universitario 12 de Octubre, Madrid, Spain

    Contact: Study coordinator (Joaquín Martínez López, MD) · jmarti01@med.ucm.es · +34 91 779 2877
    Contact: Study coordinator (Lucía Sánchez Pérez) · luciasanchez12imas@gmail.com · (+34) 91 779 28 09
    Contact: Principal Investigator (Joaquín Martínez López, MD)
  • Instituto de Investigacion Biomedica de Salamanca (IBSAL), Salamanca, Spain

    Contact: Study coordinator (Carmen Arias) · ensayosclinicos@ibsal.es · +34 92 329 1100
    Contact: Principal Investigator (Maria-Victoria Mateos Manteca, MD, PhD)